Patents by Inventor Collette Behrens

Collette Behrens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTERFERON ALPHA 2B VARIANTS
    Publication number: 20220220184
    Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
    Type: Application
    Filed: March 31, 2022
    Publication date: July 14, 2022
    Inventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
  • Interferon alpha 2B variants
    Patent number: 11319356
    Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: May 3, 2022
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
  • Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
    Patent number: 11117975
    Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: September 14, 2021
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Adam Clarke, Matthew Pollard, Anthony Gerard Doyle, Collette Behrens, Tetsuo Yamagishi, David S. Wilson, Jr., Sarah L. Pogue, Tetsuya Taura
  • INTERFERON ALPHA 2B VARIANTS
    Publication number: 20200102364
    Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 2, 2020
    Inventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
  • Interferon alpha 2B variants
    Patent number: 10544199
    Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: January 28, 2020
    Assignee: Teva Pharmaceuticals Australia Pty Ltd
    Inventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
  • ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B
    Publication number: 20180305460
    Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
    Type: Application
    Filed: April 19, 2018
    Publication date: October 25, 2018
    Inventors: Adam Clarke, Matthew Pollard, Anthony Gerard Doyle, Collette Behrens, Tetsuo Yamagishi, David S. Wilson, JR., Sarah L. Pogue, Tetsuya Taura
  • Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
    Patent number: 9963515
    Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: May 8, 2018
    Assignee: Teva Pharmaceuticals Australia Pty Ltd.
    Inventors: Adam Clarke, Matthew Pollard, Anthony Gerard Doyle, Collette Behrens, Tetsuo Yamagishi, David S. Wilson, Jr., Sarah L. Pogue, Tetsuya Taura
  • INTERFERON ALPHA 2B VARIANTS
    Publication number: 20160122410
    Abstract: The present invention provides a fusion polypeptide comprising a first domain and a second domain, wherein the first domain comprises a polypeptide ligand which binds to a cell surface-associated antigen and the second domain comprises aglycosylated interferon ? 2b (IFN?2b) having a sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The aglycosylated IFN?2b further comprises one or more amino acid substitutions or deletions which attenuate the activity of the aglycosylated IFN?2b.
    Type: Application
    Filed: October 23, 2015
    Publication date: May 5, 2016
    Inventors: Collette Behrens, Anthony Doyle, Adam Clarke, Matthew Pollard, Teresa Domagala
  • ANTI-CD38 ANTIBODIES AND FUSIONS TO ATTENUATED INTERFERON ALPHA-2B
    Publication number: 20160068612
    Abstract: Antibodies that specifically bind to CD38, as well as constructs comprising such antibodies fused to attenuated interferon alpha-2B proteins are provided. Anti-CD38-attenuated interferon alpha-2b fusion constructs may be used to inhibit proliferation in cancerous cells that express both CD38 and the receptor for IFN-alpha2b, as well as to induce apoptosis in such cells. Inhibition of proliferation and induction of apoptosis in cancerous cells may serve as the basis for the treatment of the underlying cancer.
    Type: Application
    Filed: October 26, 2015
    Publication date: March 10, 2016
    Inventors: Adam Clarke, Matthew Pollard, Anthony Gerard Doyle, Collette Behrens, Tetsuo Yamagishi, David S. Wilson, JR., Sarah L. Pogue, Tetsuya Taura